Remdesivir for the Treatment of Covid-19 — Preliminary Report

To the Editor: We would like to direct attention to the enrollment criteria in the trial described in the article by Beigel et al. (published online on May 22 at NEJM.org). 1 In patients with Covid-19–related respiratory disease, these criteria resulted in the use of remdesivir well into the illness. The median time from symptom onset to randomization was 9 days. In an analysis involving patients with community-acquired pneumonia, Daniel et al. found an increased mortality at 30 days when the time to administration of the first antibiotic was 4 hours or longer. 2 Clinicians have followed the recommendations of the Surviving . . .